Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:awards |
B Corp certification
|
| gptkbp:CEO |
Ugo Di Francesco
|
| gptkbp:country |
gptkb:Italy
|
| gptkbp:focusArea |
neonatology
rare diseases respiratory diseases |
| gptkbp:founded |
1935
|
| gptkbp:founder |
Giulio Chiesi
|
| gptkbp:headquarters_location |
Parma, Italy
|
| https://www.w3.org/2000/01/rdf-schema#label |
Chiesi Farmaceutici
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:member |
gptkb:European_Federation_of_Pharmaceutical_Industries_and_Associations_(EFPIA)
|
| gptkbp:numberOfEmployees |
over 6,000
|
| gptkbp:operatesIn |
global
|
| gptkbp:parentOrganization |
Chiesi Group
|
| gptkbp:products |
rare disease drugs
respiratory drugs neonatology drugs |
| gptkbp:revenue |
over €2 billion (2022)
|
| gptkbp:subsidiary |
gptkb:Chiesi_USA
Chiesi Canada |
| gptkbp:type |
gptkb:public_company
|
| gptkbp:website |
https://www.chiesi.com/
|
| gptkbp:bfsParent |
gptkb:pegunigalsidase_alfa
|
| gptkbp:bfsLayer |
7
|